FCGR2B and systemic lupus erythematosus: Mutations in inhibitory receptors such as the FcγRIIb or the Siglecs CD22 or Siglec-G, as well as in downstream inhibitory signaling proteins such as Lyn or SHP-1 lead to SLE-like disease in mice (24–28).